Abiraterone combined with prednisone in the treatment of high-risk high-tumor load metastatic castration-resistant prostate cancer: a case report and literature review / 现代泌尿外科杂志

【Objective】 To observe the efficacy of abiraterone (AA) in the treatment of metastatic castration-resistant prostate cancer (mCRPC). 【Methods】 The clinical data of a newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) patient with high risk and high tumor load were analyzed. After operation and endocrine therapy, the disease evolution was observed. Relevant literature was reviewed. 【Results】 After laparoscopic radical prostatectomy, 6-month bicalutamide and androgen deprivation therapy (ADT), the total prostate specific antigen (tPSA) was reduced to the lowest of 0.51 ng/mL, and then increased month by month. After domestic abiraterone (trade name: Qingkeshu) in the 8th month was administered for 4 months, tPSA continued to increase to 12.39 ng/mL. The case was then diagnosed as mCRPC. The treatment was adjusted again in the 11th mouth and the patient received AA (trade name: Zeke) combined with prednisone and ADT, and tPSA decreased to 0.17 ng/mL 2 months later. After 14 months of treatment, tPSA remained at about 0.12 ng/mL. Systemic ECT examination indicated that the range of bone metastases decreased and some areas of nuclide concentration turned shallow without obvious adverse reactions. 【Conclusion】 AA combined with prednisone and ADT can produce rapid decline in PSA and a good response in mCRPC patients. It can also significantly slow the progression of bone metastasis and relieve pain symptoms without obvious adverse reactions. Long-term efficacy needs further observation.

Clinical value of peripheral blood circulating tumor cells in the diagnosis and treatment of prostate cancer / 中国基层医药

Objective:To investigate the clinical value of peripheral blood circulating tumor cells (CTC) in the diagnosis and treatment of prostate cancer.Methods:Sixty-four patients with prostate cancer who received treatment in Xinjiang Production and Construction Corps Hospital, China between June 2018 and May 2020 were included in the cancer group. An additional 35 patients with benign prostatic lesions who concurrently received treatment in the same hospital were included in the benign disease group. Twenty male patients with non-prostate disease were included in the control group. Cell enrichment, separation, staining and identification together with Gleason score and pathological stage were subjected to one-way analysis of variance.Results:The percentage of patients with CTC count ≥ 3 in the cancer, benign disease and control groups was 73.43% (47/64), 17.14% (6/35) and 10.00% (2/20), respectively. The level of prostate-specific antigen in patients with CTC was significantly higher than that in patients without CTC ( t = 2.89, P < 0.05). There was significant difference in CTC count between different Gleason score groups ( F = 3.25, P < 0.05) and between different pathological stage groups ( F = 3.42, P < 0.05). Conclusion:Peripheral blood CTC measurement can be used as an auxiliary method for the differentiation of benign and malignant prostate diseases. CTC count in patients with prostate cancer is correlated with prostate-specific antigen level, Gleason score, and pathological stage. Therefore, peripheral blood CTC measurement plays an auxiliary role in predicting prognosis in patients with CTC. This study is innovative and scientific.

Clinicopathological features, diagnosis and treatment of primary and metastatic hepatic neuroendocrine neoplasm originating from digestive tract / 中华消化杂志

Objective@#To explore the clinicopathological characteristics of primary hepatic neuroendocrine neoplasm (HNEN) and metastatic HNEN from digestive tract, to screen the risk factors of hepatic metastasis of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) and to analyze the differences between primary and metastatic HNEN in clinical features, diagnosis, treatment and prognosis.@*Methods@#From January 2010 to June 2017, the clinical data of 182 patients with HNEN admitted at The First Affiliated Hospital of Zhengzhou University were retrospectively analyzed, including 39 cases of primary HNEN, 129 cases of metastatic HNEN and 14 cases of HNEN with unknown primary lesions. Chi-square test and t test were performed to analyze the pathologic characteristics among groups. Logistic regression method was used to analyze the risk factors of hepatic metastasis. Kaplan-Meier method and log-rank test were used for survival analysis. Cox model was used for the prognostic multivariate survival analysis.@*Results@#Metastatic HNEN from digestive tract was more common in male (70.5%, 91/129). The case number of serological tumor biomarkers neuronspecific enolase and alpha-fetoprotein positive in primary HNEN were two cases and one case, respectively, and the positive rates in metastatic HNEN were 37.2% (32/86) and 6.4% (7/110). Most primary HNEN was single lesion (61.5%, 24/39), while multiple lesions were more common in metastatic HNEN (78.3%, 90/115). Primary HNEN mainly occurred in the right lobe of the liver (44.7%, 17/38), while metastatic HNEN located simultaneously in the left and right lobes of the liver (68.4%, 78/114). There were significant differences between primary HNEN and metastatic HNEN in tumor number, pathological grading, location of tumors and maximum diameter of tumors (χ2=21.264, 11.696, 19.461 and 4.547, all P<0.05). The median survival time of patients with primary HNEN and metastatic HNEN were 17.0 months and 10.0 months, and there was a significant difference in survival curves between the two groups (χ2=7.235, P=0.007). The type of hepatic tumors (primary or metastatic)(P=0.002), pathological grading of hepatic tumors (P=0.044), lymph node metastasis (P=0.024), the growth pattern of tumors (P<0.01) and treatment methods (P=0.018) were the independent factors for the prognosis of patients.@*Conclusions@#There are significant differences between primary HNEN and metastatic HNEN in tumor number, size and location. The type of hepatic tumors, pathological grading, lymph node metastasis, growth pattern of tumors and treatment methods are the independent factors for the prognosis of patients. Early topical treatment and combination treatment can help to prolong survival time of HNEN patients.

Clinicopathological features, diagnosis and treatment of primary and metastatic hepatic neuroendocrine neoplasm originating from digestive tract / 中华消化杂志

Objective To explore the clinicopathological characteristics of primary hepatic neuroendocrine neoplasm (HNEN) and metastatic HNEN from digestive tract ,to screen the risk factors of hepatic metastasis of gastroenteropancreatic neuroendocrine neoplasm (GEP-NEN) and to analyze the differences between primary and metastatic HNEN in clinical features , diagnosis, treatment and prognosis.Methods From January 2010 to June 2017, the clinical data of 182 patients with HNEN admitted at The First Affiliated Hospital of Zhengzhou University were retrospectively analyzed , including 39 cases of primary HNEN, 129 cases of metastatic HNEN and 14 cases of HNEN with unknown primary lesions .Chi-square test and t test were performed to analyze the pathologic characteristics among groups .Logistic regression method was used to analyze the risk factors of hepatic metastasis .Kaplan-Meier method and log-rank test were used for survival analysis . Cox model was used for the prognostic multivariate survival analysis .Results Metastatic HNEN from digestive tract was more common in male ( 70.5%, 91/129 ).The case number of serological tumor biomarkers neuronspecific enolase and alpha-fetoprotein positive in primary HNEN were two cases and one case , respectively, and the positive rates in metastatic HNEN were 37.2%( 32/86) and 6.4%(7/110).Most primary HNEN was single lesion (61.5%, 24/39), while multiple lesions were more common in metastatic HNEN (78.3%, 90/115).Primary HNEN mainly occurred in the right lobe of the liver (44.7%, 17/38), while metastatic HNEN located simultaneously in the left and right lobes of the liver (68.4%, 78/114).There were significant differences between primary HNEN and metastatic HNEN in tumor number , pathological grading, location of tumors and maximum diameter of tumors ( χ2 ＝21.264, 11.696, 19.461 and 4.547, all P?0.05).The median survival time of patients with primary HNEN and metastatic HNEN were 17.0 months and 10.0 months, and there was a significant difference in survival curves between the two groups (χ2 ＝7.235, P＝0.007).The type of hepatic tumors (primary or metastatic) ( P＝0.002), pathological grading of hepatic tumors (P＝0.044), lymph node metastasis ( P ＝0.024), the growth pattern of tumors ( P ?0.01) and treatment methods (P＝0.018) were the independent factors for the prognosis of patients .Conclusions There are significant differences between primary HNEN and metastatic HNEN in tumor number , size and location. The type of hepatic tumors, pathological grading , lymph node metastasis, growth pattern of tumors and treatment methods are the independent factors for the prognosis of patients .Early topical treatment and combination treatment can help to prolong survival time of HNEN patients .

Curative effect of paraquat detoxification recipe combined with continuous hemoperfusion in the treatment of patients with APP and clinical value of Presepsin / 中华危重病急救医学

Objective To investigate the clinical effect of paraquat (PQ) detoxification recipe combined with continuous hemoperfusion (HP) in the treatment of patients with acute paraquat poisoning (APP) and clinical significance of soluble CD14 subtype (sCD14-st, Presepsin). Methods A prospective randomized controlled trial was conducted. 152 patients with moderate APP admitted to Department of Emergency Medicine of Harrison International Peace Hospital Affiliated to Hebei Medical University from July 2013 to June 2017 were enrolled, and they were randomly divided into three groups. The patients in HP group (group A, n = 35) only received 2-hour HP for 3 times, 8 hours each time, those in PQ detoxification recipe combined with HP group (group B, n = 50) received PQ detoxification recipe 1 (once per 2 hours until no PQ component was found in faeces) and 2 (3 times a day for 14 days) beside HP. The others in PQ detoxification recipe combined with persistent HP group (group C, n = 67) received continuous HP until the PQ component in serum was not detected. The parameters of organ function and inflammatory factor, and blood Presepsin and PQ contents were determined before and after treatment. The curative effect and 28-day mortality were recorded. The correlations between serum Presepsin level and PQ content as well as 28-day mortality were analyzed with Pearson correlation analysis. Receiver operating characteristic curve (ROC) was plotted to analyze the predictive value of Presepsin on prognosis. Results The total effective rate of group C was significantly higher than that of groups A and B [70.1% (47/67) vs. 34.3% (12/35), 54.0% (27/50)], and 28-day mortality was significantly lowered [29.8% (20/67) vs. 65.7% (23/35), 46.0% (23/50), both P < 0.05]. There was no significant difference in alanine aminotransferase (ALT), MB isoenzyme of creatine kinase (CK-MB), serum creatinine (SCr), C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukins (IL-6 and IL-10) before treatment among the three groups. Five days after treatment, the above parameters in the three groups were increased as compared with those before treatment, but the increase degree in group C was the lowest. At 7 days after treatment, the parameters were decreased, especially in group C. There was no significant difference in serum Presepsin and PQ levels before treatment among the three groups. With the prolongation of treatment time, the Prespsin levels in groups A, B, and C were increased, and peaked at 12 hours (μg/L: 4.28±0.20, 3.87±0.25, 3.53±0.23), then gradually decreased,and the PQ contents were lower than those before treatment from 8 hours (mg/L: 1.76±0.12 vs. 2.12±0.17, 1.57±0.08 vs. 2.24±0.16, 1.25±0.10 vs. 2.14±0.18), with a time dependence pattern, especially in group C (all P < 0.05) . Correlation analysis showed that blood Presepsin level was positively correlated with PQ content and 28-day mortality (r1= 0.917, r2= 0.864, both P = 0.001), suggesting that the higher the PQ content was, the higher the Presepsin level, and the higher the 28-day mortality was. ROC curve analysis showed that the area under ROC curve (AUC) of Presepsin predicting 28-day mortality was 0.863; when the cut-off value was 1.22 μg/L, the sensitivity was 83.3%, the specificity was 81.4%, the positive predictive value was 77.46%, and the negative predictive value was 86.42%. Conclusions Early administration of PQ detoxification recipe combined with continuous HP treatment can effectively reduce Presepsin level, decrease the mortality of patients with moderate APP, improve the prognosis. Presepsin can assess the prognosis of patients with APP.

Incidence and prognosis of esophageal adenocarcinoma, Siewert type Ⅰ adenocarcinoma of esophagogastric junction and Barrett esophagus in Henan province from 2010 to 2015 / 中华消化杂志

Objective To explore the incidence and prognosis of esophageal adenocarcinoma (EAC),Siewert type Ⅰ adenocarcinoma of esophagogastric junction (AEG) and Barrett esophagus (BE) in Henan province,an area of high incidence of esophageal cancer.Methods From January 2010 to January 2015,the clinical data of 152 patients with EAC,70 patients with Siewert type Ⅰ AEG and 149 patients with BE were collected,and the clinicopathological features and treatment methods of all the patients were retrospectively analyzed.Patients with EAC and Siewert type Ⅰ AEG were followed up by telephone,while the patients with BE were followed up by telephone and endoscopy examination.The follow-up was ended in January 1st 2016 and the total follow-up period was 12 to 72 months.Chi square test,t test and one way analysis of variance were performed for comparison of pathological characteristics among groups;linear regression method was used to detect changing trends in the rates over time and Kaplan-Meier method was for survival analysis.Results The annual detection rates in five years of EAC were 0.7‰,0.9‰,0.8‰,1.1‰ and 1.1‰,respectively,suggesting an increasing trend (F=10.714,P＜0.05).The proportion of EAC to esophageal squamous carcinoma (ESC) were 2.9％,3.2％,3.1％,3.4％ and 3.8％,respectively with an increasing trend (F=17.647,P＜0.05).The one,three-and five-year overall survival rates of EAC were 57.7％,30.6％ and 15.3 ％.Among 152 patients with EAC,51 received operation and 101 patients did not.The median survival time was 14 months,and the median survival time of operation group and non-operation group was 60 months and 10 months,respectively.Survival curve layered by treatment methods indicated that the three-year survival rates of operation combined with chemotherapy group,operation group,radiotherapy or chemotherapy group and notreatment group were 82.3％,50.0％,11.2％ and 0.The three-year survival rates in operation combined with chemotherapy group,operation group,radiotherapy or chemotherapy group and no-treatment group were significantly different (x2 =1.099,2.236 and 11.431,all P＜0.01).The annual detection rates in five years of Siewert type Ⅰ AEG were 0.2‰,0.3‰,0.4‰,0.4‰,0.7‰,respectively,with an increasing trend (F=19.105,P＜0.05).The one-,three-and five-year overall survival rate of Siewert type Ⅰ AEG was 59.8％,30.5 ％ and 15.3 ％,respectively.Among 70 patients with Siewert type Ⅰ AEG,16 cases received operation,while 54 cases without operation.The median survival time of Siewert type Ⅰ AEG was 16 months,and the median survival time of operation group and non-operation group was 50 months and 13 months.The one-,three-and five-year survival rates of operation group were 87.5％,62.6％ and 43.0％ respectively,and the one-,threeand five-year survival rates of non-operation group were 50.2 ％,19.6 ％ and 0,respectively,and the difference in cumulative survival rate between the two groups was statistically significant (x2 =12.289,P＜ 0.05).The annual detection rates of BE in five years were 0.6‰,0.5‰,0.9‰,0.9‰ and 1.1‰,respectively,with an increasing trend (F=13.364,P＜0.05).Among 149 patients with BE,there were 24 cases with specialized intestinal metaplasia and six cases with dysplasia,but none of them developed into adenocarcinoma during the follow-up period.Conclusions In Henan province,an area with high incidence of esophageal cancer,there is an increasing trend in the annual detection rates in five years of EAC,Siewert type Ⅰ AEG and BE.Although the incidence of EAC and Siewert type Ⅰ AEG is not high,the prognosis is poor with low survival rate.The prognosis of non-operation group is obviously worse than that of operation group.Specialized intestinal metaplasia and dysplasia in patiens with BE are rare and have a low probability of developing into adenocarcinoma.

Incidence and prognosis of esophageal adenocarcinoma, Siewert type Ⅰ adenocarcinoma of esophagogastric junction and Barrett esophagus in Henan province from 2010 to 2015 / 中华消化杂志

Objective To explore the incidence and prognosis of esophageal adenocarcinoma (EAC),Siewert type Ⅰ adenocarcinoma of esophagogastric junction (AEG) and Barrett esophagus (BE) in Henan province,an area of high incidence of esophageal cancer.Methods From January 2010 to January 2015,the clinical data of 152 patients with EAC,70 patients with Siewert type Ⅰ AEG and 149 patients with BE were collected,and the clinicopathological features and treatment methods of all the patients were retrospectively analyzed.Patients with EAC and Siewert type Ⅰ AEG were followed up by telephone,while the patients with BE were followed up by telephone and endoscopy examination.The follow-up was ended in January 1st 2016 and the total follow-up period was 12 to 72 months.Chi square test,t test and one way analysis of variance were performed for comparison of pathological characteristics among groups;linear regression method was used to detect changing trends in the rates over time and Kaplan-Meier method was for survival analysis.Results The annual detection rates in five years of EAC were 0.7‰,0.9‰,0.8‰,1.1‰ and 1.1‰,respectively,suggesting an increasing trend (F=10.714,P＜0.05).The proportion of EAC to esophageal squamous carcinoma (ESC) were 2.9％,3.2％,3.1％,3.4％ and 3.8％,respectively with an increasing trend (F=17.647,P＜0.05).The one,three-and five-year overall survival rates of EAC were 57.7％,30.6％ and 15.3 ％.Among 152 patients with EAC,51 received operation and 101 patients did not.The median survival time was 14 months,and the median survival time of operation group and non-operation group was 60 months and 10 months,respectively.Survival curve layered by treatment methods indicated that the three-year survival rates of operation combined with chemotherapy group,operation group,radiotherapy or chemotherapy group and notreatment group were 82.3％,50.0％,11.2％ and 0.The three-year survival rates in operation combined with chemotherapy group,operation group,radiotherapy or chemotherapy group and no-treatment group were significantly different (x2 =1.099,2.236 and 11.431,all P＜0.01).The annual detection rates in five years of Siewert type Ⅰ AEG were 0.2‰,0.3‰,0.4‰,0.4‰,0.7‰,respectively,with an increasing trend (F=19.105,P＜0.05).The one-,three-and five-year overall survival rate of Siewert type Ⅰ AEG was 59.8％,30.5 ％ and 15.3 ％,respectively.Among 70 patients with Siewert type Ⅰ AEG,16 cases received operation,while 54 cases without operation.The median survival time of Siewert type Ⅰ AEG was 16 months,and the median survival time of operation group and non-operation group was 50 months and 13 months.The one-,three-and five-year survival rates of operation group were 87.5％,62.6％ and 43.0％ respectively,and the one-,threeand five-year survival rates of non-operation group were 50.2 ％,19.6 ％ and 0,respectively,and the difference in cumulative survival rate between the two groups was statistically significant (x2 =12.289,P＜ 0.05).The annual detection rates of BE in five years were 0.6‰,0.5‰,0.9‰,0.9‰ and 1.1‰,respectively,with an increasing trend (F=13.364,P＜0.05).Among 149 patients with BE,there were 24 cases with specialized intestinal metaplasia and six cases with dysplasia,but none of them developed into adenocarcinoma during the follow-up period.Conclusions In Henan province,an area with high incidence of esophageal cancer,there is an increasing trend in the annual detection rates in five years of EAC,Siewert type Ⅰ AEG and BE.Although the incidence of EAC and Siewert type Ⅰ AEG is not high,the prognosis is poor with low survival rate.The prognosis of non-operation group is obviously worse than that of operation group.Specialized intestinal metaplasia and dysplasia in patiens with BE are rare and have a low probability of developing into adenocarcinoma.

Relationship between expression of EGFR in gastric cancer tissue and clinicopathological features

OBJECTIVE@#To investigate the relationship between the expression of epidermal growth factor receptor (EGFR) in gastric cancer and the clinicopathological features and prognosis.@*METHODS@#A total of 78 paraffin specimens of gastric cancer operation were collected. The immunohistochemical method was used to detect the expression of EGFR in 78 cases of gastric cancer and 20 cases of adjacent normal tissue. The relationship between the high expression of EGFR and clinicopathological features was analyzed.@*RESULTS@#EGFR positive expression rate in the 78 cases of gastric cancer tissue was 57.7 % (45/78), while EGFR was not expressed in 20 cases of adjacent normal tissue. The high EGFR expression was positively correlated with the position of gastric cancer, tumor size, cell differentiation, invasive depth, lymph node metastasis and TNM staging, yet having no obvious relation with gender or age.@*CONCLUSIONS@#EGFR expression level in gastric cancer is closely related to the incidence and development of gastric cancer, which can provide a theoretical basis for the targeted therapy for gastric cancer with EGFR as the target.

Expression of IGF-1R in esophageal squamous cell carcinoma and the effect of its silencing by siRNA on the proliferation of esophageal cancer EC9706 cells in vitro / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To explore the correlation of IGF-1R expression with clinical features of esophageal squamous cell carcinoma (ESCC) and to investigate the effect of silencing IGF-1R by siRNA on the proliferation of esophageal cancer cell line EC9706 cells.</p><p><b>METHODS</b>Immunohistochemistry was used to detect the expresion of IGF-1R in 80 specimens of ESCC and 18 specimens of normal esophageal mucosa. IGF-1R siRNA was transfected into esophageal squamous cell carcinoma EC9706 cells, and the effect of RNAi was assessed by Western blot. The proliferation of EC9706 cells was determined by drawing growth curve, MTT assay and plate colony-forming assay.</p><p><b>RESULTS</b>The total and strong positive rates of IGF-1R expression were 86.3% and 51.3% in ESCC, and 61.1% and 11.1% in normal esophageal epithelium, respectively. The total and strong positive rates of IGF-1R expression in patients with lymph node metastasis were 94.4% and 74.1%, significantly higher than 69.2% and 3.9%, respectively, in those without lymph node metastasis (P<0.01). A significantly higher IGF-1R expression was associated with lower histological grade (P<0.05). The total and strong rates of IGF-1R expression in 39 patients of stages III and IV were 97.4% and 71.8% , significantly higher than the 75.6% and 31.7%, respectively, in 41 cases of stages I and II (P<0.01). IGF-1R RNAi significantly inhibited IGF-1R expression and the growth of EC9706 cells. The clone formation rate of RNAi-IGF-1R transfected cells was 19.1%, significantly lower than that of 52.3% in non-transfected cells and 49.0% in empty vector-transfected EC9706 cells (P<0.05).</p><p><b>CONCLUSIONS</b>The overexpression of IGF-1R is colerated with lymph node metastasis, differentiation and clinical stage. Down-regulation of IGF-1R can inhibit the proliferation of esophageal cancer EC9706 cells in vitro.</p>

Expression of ERCC1 mRNA and its impact on the prognosis of patients with non-small cell lung cancer / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To investigate the level of ERCC1 mRNA expression in non-small cell lung cancer and analyze the influencing factors of the survival of patients after operation.</p><p><b>METHODS</b>The level of ERCC1 mRNA expression was quantified in sixty pairs of non-small cell lung cancer tissue and their matched normal lung tissues by real-time PCR assay. The survival of patients was analyzed by univariate Kaplan-Meier and Cox regression analysis.</p><p><b>RESULTS</b>The level of ERCC1 mRNA expression in cancer tissues (-7.85 ± 3.86) was significantly higher than that in matched normal ones (-11.19 ± 5.03;t = 3.973, P = 0.000). Up-regulation of ERCC1 mRNA was found in 43 of 60 (71.7%) lung cancer tissues compared with that in the matched normal lung tissues (17 of 60, 28.3%). The univariate survival analysis by Kaplan-Meier method showed that the survival rate of patients with high ERCC1 mRNA expression was lower than that in the patients with low expression of ERCC1 mRNA (P = 0.000). Patients with lymph node metastasis, smoking, cancer family history, or high pathological grade had significantly shorter survaival time than those without lymph node metastasis, smoking, cancer family history, or with low pathological grade. Cox regression survival analysis showed that the level of ERCC1 mRNA expression, lymph node metastasis, smoking, and pathological grade were significant independent factors affecting the survival rate.</p><p><b>CONCLUSIONS</b>Non-small cell lung cancer patients with up-regulated ERCC1 expression have a poor survival. The expression of ERCC1 mRNA, lymph node metastasis, pathological grade, cancer family history and smoking can be used as prognostic indicator of non-small cell lung cancer.</p>

Analysis of a survey result on the state of Kashin-Beck disease in Tibet / 中国地方病学杂志

ObjectiveTo investigate the distribution of Kashin-Beck disease(KBD) in Tibet, and assess the disease status. Methods Between 2007 and 2008, a survey was done on KBDepidemiology which was carried out in four prefectures of 26 counties according to the east, south, west, north and center in Nakchu,Lhoca, Nyingtri and Shigatse districts of Tibet, with towns and villages as baseline survey points. According to the KBD e survey scheme, KBD clinical examination for adults was also carried out and at the same time clinical and right hand anteroposterior X-ray examinations were given to children aged 4 - 13. The partition of endemic area was based on the criteria of national standards for Kashin-Beck disease diagnoses《GB 16395-1996》. Slight KBD area:clinical prevalence of Kashin-Beck disease grade Ⅰ and above was less than 10％ or X-ray detection rate ＜ 10％ of children; the moderate prevalent KBD area: clinical prevalence of Kashin-Beck disease grade Ⅰ and above was between 10％ and 20％ or X-ray detection rate was between 10％ and 30％ of children; severe KBD area: clinical prevalence of KBD grade Ⅰ and above was more than 20％ or X-ray detection rate was higher than 30％ of children.ResultsA total of 108 townships of 26 counties were surveyed, 14 686 adults were clinically examined, cases detection of grade Ⅰ and above were 637 people, the prevalence was 4.34％, and no case of grade Ⅲ was detected.Of 5769 children's right anteroposterior X-ray film, 102 were detected positive; the prevalence rate was 1.77％.Metaphysis was affected in most of the child cases, which accounting for 89.2％ (91/102). Amongst all the counties, there were 10 counties, clinical detection rate of adult KBD was 0, and children's X-ray detection rate of KBD was also 0. In 1 county the clinical prevalence rate for adults KBD was 0 and X-ray detection rate for children was 3.66(7/191 ). In 12 counties the clinical prevalence rate for adults KBD was between 1.03％ and 7.54％, X-ray detection rate for children was between 0 and 7.76％, amongst all these counties surveyed there were 5 counties,the detection rate for children was 0. In 3 counties the clinical prevalence rate for adult KBD was between 10.69％and 13.88％, the X-ray detection rate for children was between 5.31％ and 7.76％. Conclusions According to the criteria for diagnoses of KBD, within the 26 counties surveyed, 10 counties are non-endemic areas, 13 counties are slight endemic areas, 3 counties are medium endemic areas. So far, KBD is prevalent in 52 counties of 7 prefectures (cities) in Tibet, the disease is widely distributed, the situation is still severe, and there is a need to continue to strengthen KBD surveillance.

Insulin induces anticancer cytotoxicity of 5-Fu to two human colon cancer cell lines / 中华肿瘤杂志

<p><b>OBJECTIVE</b>To explore the possibility of use of insulin as a potentiator of 5-Fu to human colon cancer cell lines HCT-8 and HT-29 and study its mechanism.</p><p><b>METHODS</b>MTT assay was used to examine the inhibition rate of cell growth after treatment with 5-Fu and insulin. Cell cycle was determined by flow cytometry.</p><p><b>RESULTS</b>Insulin showed an enhancing effect on the chemotherapeutic response of 5-Fu when insulin was applied at a dose of exceeding 0.8 mU/ml 0 approximately 8 h before 5-Fu. Within the range of from 0.8 mU/ml to 8 mU/ml, a higher concentration of insulin gave a higher proportion of inhibited cells. But when the insulin concentration exceeds 8 mU/ml, the proportion became stable as that of 8 mU/ml. Insulin increased the percentage of S phase cells and decreased the percentage of G(1) phase cells (P < 0.01). The percentage of S phase cells reached a peak when the cells were treated with insulin for 6 hours.</p><p><b>CONCLUSION</b>Insulin can enhance the anticancer toxicity of 5-Fu to human colon cancer cell lines HCT-8 and HT-29 cells. Insulin increases the percentage of S phase cells, which may be one of the main mechanisms of insulin-induced enhancement of anticancer response of cancer cells to 5-Fu chemotherapy.</p>

Oxaliplatin and teniposide inhibited proliferation and induced apoptosis of gastric cancer cell line BGC-823 / 肿瘤

Objective:To investigate the effects of oxaliplatin (OXA) and teniposide (VM-26) on proliferation and apoptosis of gastric cancer cell line BGC-823.Methods:MTT assay was used to examine the inhibition rate of cell growth when cells were treated at various concentrations of OXA and VM-26 alone or in combination. The apoptosis was examined by flow cytometry (FCM). The protein expression of cell apoptosis associated proteins caspase-9 and livin were examined by immunocytochemistry. Results:OXA or VM-26 effectively inhibited the growth of BGC-823 gastric cancer cells in a concentration-dependent manner at certain range of concentrations. The inhibitory rate of combined treatment with OXA and VM-26 was significantly higher than that of OXA or VM-26 alone (P<0.05). The value of combination index (CI) was 0.46. The rate of apoptosis cells induced by 1.25 μg/mL OXA was 6.13%, 13.86% and 21.48% at 12, 24 and 48 h. The apoptosis rate induced by 0.625 μg/mL VM-26 was 4.60%, 10.72% and 17.07% for 12, 24 and 48 h. In combined treatment group the apoptosis rate was 11.73%, 24.14% and 44.75% at 12, 24 and 48 h, respectively. The difference was significant between combined treatment group and single drug treatment group (P<0.05). Immunnocytochemical analysis showed that the expression of caspase-9 protein was up-regulated after being exposed to OXA (1.250 μg/mL) or OXA plus VM-26 (0.750 μg/mL), while the expression rate of livin protein was down-regulated. There were significant differences among different treatment groups as well as between treatment groups and control group (P<0.05).Conclusion:OXA combined with VM-26 has synergistic effects in inhibiting the growth and inducing apoptosis of gastric cancer BGC-823 cells.

Diagnostic significance of cytokeratin 19 and 20 expression on micrometastasis of colorectal cancer / 中华胃肠外科杂志

<p><b>OBJECTIVE</b>To inquire into the diagnostic significance of cytokeratin 19(CK19) and cytokeratin 20(CK20) expression on hematogenous micrometastasis of colorectal cancer.</p><p><b>METHODS</b>Forty-four patients with colorectal cancer were collected as colorectal cancer groups, and another 18 patients treated with abdominal surgical operations because of benign diseases were collected as benign disease group. Blood of all the patients was harvested from their portal and peripheral veins, and CK19 and CK20 levels in the blood were determined by RT-PCR.</p><p><b>RESULTS</b>There were no positive expression of CK19 and CK20 in the portal and peripheral blood of all the patients in benign disease group. Of the colorectal cancer group, 34 patients(77.3%) appeared positive expressions of CK19 and/or CK20 in portal and peripheral blood, and there was significant difference in the expressions of CK19 and CK20 between the two groups(P<0.05). Within the colorectal cancer group, the positive expression rates of CK19 and CK20 in peripheral blood were 36.4% and 52.3%, and the rates in portal blood were 59.1% and 72.7%. The rates of portal blood were significantly higher than those of peripheral blood(P<0.05). The positive expression rate in patients at stage III( was significantly higher than that in patients at stage I( orII( (P<0.05). The postoperative metastasis and recurrence rate of colorectal cancer in patients with positive expression of CK19 and CK20 in peripheral blood was 61.5%, which was significantly higher than that(25.0%) in patients with positive expression in portal blood only(P<0.05).</p><p><b>CONCLUSIONS</b>In patients with colorectal cancer, the expressions of CK19 and CK20, which are determined by RT-PCR in blood from portal and peripheral veins, are the sensitive and specific indexes for diagnosing hematogenous micrometastasis of the cancer.</p>

The effect of TNF-related apoptosis-inducing ligand on the activity of nuclear kappa B in prostate cancer cell line PC-3M / 中国病理生理杂志

AIM:To investigate the activation and inactivation of nuclear factor kappa B(NF-κB)when tumor necrosis factor-related apoptosis-inducing ligand(TRAIL)is applied to induce the apoptosis of androgen-independent prostate cancer cell line PC-3M.METHODS:After the treatment of TRAIL or LPS at different doses,we tested the nuclear translocation of NF-κB by cell immunohistochemical staining and electrophoretie mobility shift assay(EMSA),and evaluated the level of IκB by RT-PCR under pyrrolidine dithiocarbamate(PDTC)treatment.RESULTS:EMSA and cell immunohistochemical analysis showed that the translocation of NF-κB was significantly activated when PC-3M cells were treated with TRAIL or LPS(P＜0.05).The pretreatment of PDTC upregulated the expression of IκB and blocked the nuclear translocation of NF-κB.CONCLUSION:TRAIL remarkably stimulates the activation of nuclear NF-κB in androgen-independent prostate cancer cells.On the other hand,the translocation of NF-κB can be significantly and efficiently inhibited in PC-3M cells by pretreatment with PDTC.The increased expression of IκB might be a clue for this inhibition,which means the possible way to enhance the effect of TRAIL in the apoptosis of prostate cancer cells.